Cargando…
The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
Waldenström’s macroglobulinemia (WM) remains an incurable malignancy. However, a number of treatment options exist for patients with WM, including alkylating agents, anti-CD20 monoclonal antibodies, and small molecule inhibitors such as proteasome inhibitors and Bruton tyrosine kinase inhibitors (BT...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146645/ https://www.ncbi.nlm.nih.gov/pubmed/35629099 http://dx.doi.org/10.3390/jpm12050676 |